Targeting RAS oncogenesis with SOS1 inhibitors.

Hillig, Roman Christian; Bader, Benjamin

Hillig, Roman Christian; Bader, Benjamin.

Affiliation

Hillig RC; Structural Biology, Lead Discovery, Nuvisan ICB GmbH, Berlin, Germany. Electronic address: roman.hillig@nuvisan.com.
Bader B; Screening, Lead Discovery, Nuvisan ICB GmbH, Berlin, Germany.

Adv Cancer Res ; 153: 169-203, 2022.

Article in En | MEDLINE | ID: mdl-35101230

Subject(s)

Neoplasms; SOS1 Protein; ras Proteins; Carcinogenesis; Humans; Neoplasms/drug therapy; Neoplasms/genetics; Neoplasms/metabolism; Oncogenes; SOS1 Protein/antagonists & inhibitors; SOS1 Protein/chemistry; SOS1 Protein/metabolism; ras Proteins/genetics; ras Proteins/metabolism

Key words

Activator; Cancer; Combination therapy; GEF; Guanine nucleotide exchange factor; KRAS; RASopathies; SOS1; Small molecule inhibitor; Son of sevenless

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ras Proteins / SOS1 Protein / Neoplasms Limits: Humans Language: En Journal: Adv Cancer Res Year: 2022 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google